494
Views
9
CrossRef citations to date
0
Altmetric
Clinical Science

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

, , , , , , , , , , , , , , , & show all
Pages 170-177 | Received 11 Feb 2008, Accepted 17 Apr 2008, Published online: 08 Jul 2009

References

  • Howard B. V., Rodrigues B. L., Bennett P. H. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: epidemiology. Circulation 2002; 105: e132–e137
  • Kannel W. B., Wilson P. W., Zhang T. J. The epidemiology of impaired glucose tolerance and hypertension. Am. Heart J 1991; 121: 1268–73
  • Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217–23
  • Zimmet P., Alberti K. G. M. M., Shaw J. Global and societal implications of the diabetic epidemic. Nature 2001; 414: 782–7
  • Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6
  • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Eng J Med 2000; 342: 145–53
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research groups. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75
  • Hansson L., Hedner T., Lund‐Johansen P., Kjeldsen S. E., Lindholm L. H., Syvertsen J. O., et al. Randomised trial of effects of calcium antagonists compared with diuretics and β‐blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356: 359–65
  • Brown M., Palmer C. R., Castaigne A., de Leeuw P. W., Mancia G., Rosenthal T., Ruilope L. M. Morbidity and mortality in patients randomized to double‐blind treatment with a long‐acting calcium‐channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research groups. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97
  • Opie L. H., Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453–8
  • Mancia G., Grassi G., Zanchetti A. New onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
  • Mann J., Julius S., for the VALUE Trial Group. The Valsartan Antihypertensive Long‐term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and Design. Blood Press 1998; 7: 176–83
  • Kjeldsen S. E., Julius S., Brunner H. R., Hansson L., Henis M., Ekman S., et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press 2001; 10: 83–91
  • Julius S., Kjeldsen S. E., Brunner H. R., Hansson L., Platt F., Ekman S., , for the Value Trial, et al. VALUE Trial: Long‐term BP trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens 2003; 16: 544–8
  • Julius S., Kjeldsen S. E., Weber M. A., Brunner H. R., Ekman S., Hansson L., , for the VALUE trial group, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022–31
  • Weber M. A., Julius S., Kjeldsen S. E., Brunner H. R., Ekman S., Hansson L., , for the VALUE trial group, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 1047–9
  • Kjeldsen S. E., Julius S., Mancia G., McInnes G. T., Hua T., Weber M. A., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes mellitus in high‐risk hypertensives patients: The VALUE trial. J Hypertens 2006; 24: 1405–12
  • Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
  • Lindholm L. H., Ibsen H., Borch‐Johnsen K., Hecht Olsen M., Wachtell K., Dahlöf B., et al. Risk of new‐onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–86
  • WHO. Department of Non‐Communicable Disease Surveillance. WHO 1999 criteria for diagnosis of diabetes mellitus. WHO, Geneva 1999; 1–59
  • Aksnes T. A., Rostrup M., Kjeldsen S. E., Störset Ø., Hua A., Julius S. Predictors of diabetes in high risk hypertensive patients in the Value Trial. J Human Hypertens 2008, in press
  • Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., , for the SCOPE Study Group, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double‐blind intervention trial. J. Hypertens 2003; 21: 875–86
  • Bosch J., Yusuf S., Gerstein H. C., Pogue J., Sheridan P., Dagenais G., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551–62
  • NAVIGATOR information site. Available from http://www.bioportfolio.com/news/novartis1.htm. 2004/10/24
  • Julius S., Gudbrandsson T., Jamerson K. A., Tariq S. S., Andersson O. The hemodynamic link between insulin resistance and hypertension. J. Hypertens 1991; 9: 983–6
  • Aksnes T. A., Reims H., Gupta S., Moan A., Os I., Kjeldsen S. E. Improved insulin sensitivity with the angiotensin II‐receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006; 20: 860–6
  • Carlsson P‐O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127–33
  • Sharma A. M., Janke J., Gorzelniak K., Engeli S., Luft F. C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609–11
  • Elliott W. J., Meyer P. M. Incident diabetes in clinical trials of antihypertensive drugs: A network meta‐analysis. Lancet 2007; 369: 201–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.